NEWS IN BRIEF

Ardena: M&A growth fuels HQ expansion

By Flora Southey

- Last updated on GMT

Ardena HQ, Belgium
Ardena HQ, Belgium

Related tags CDMO Belgium

CDMO Ardena has moved into larger headquarters in Gent, Belgium, to “free up space for additional laboratories”, says CEO.

According to the contract development and manufacturing organisation (CDMO), a sustained period of growth, driven by mergers and acquisitions, prompted the move.

“After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35m ($39.7m) sales target for 2018 ​as part of our wider strategy to become a leading integrated drug development company,”​ said CEO Harry Christiaens.

Ardena was formed in 2017, as the result of a merger between Pharmavize, Crystallics and Analytical Biochemical Laboratory (ABL).

The CDMO has since integrated active pharmaceutical ingredient (API) and nanomedicine maker, ChemConnection​, as well as API and excipient-focused Syntagon​ into its business.

Christiaens continued: “This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities.

“It will also provide a base for our staff training centre to ensure we develop our team.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...